1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Alzheimer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Alzheimer Therapeutics Market Revenue and Volume Forecast, by Product Type
8.1.1. Cholinesterase Inhibitors
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. NMDA Receptor Antagonist
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Cholinesterase + NMDA Combinations
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Anti-Amyloid Monoclonal Antibodies
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Others (Symptomatic Adjuncts)
8.1.5.1. Market Revenue and Volume Forecast
9.1. Alzheimer Therapeutics Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
9.1.1. Mild Cognitive Impairment (MCI) Due to Alzheimer’s
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Mild to Moderate Alzheimer’s Disease
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Moderate to Severe Alzheimer’s Disease
9.1.3.1. Market Revenue and Volume Forecast
10.1. Alzheimer Therapeutics Market Revenue and Volume Forecast, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Transdermal
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Intravenous (IV)
10.1.3.1. Market Revenue and Volume Forecast
11.1. Alzheimer Therapeutics Market Revenue and Volume Forecast, by End User
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Online Pharmacy
11.1.3.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Product Type
12.1.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.1.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.4. Market Revenue and Volume Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Product Type
12.1.5.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.5.4. Market Revenue and Volume Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Product Type
12.1.6.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.6.4. Market Revenue and Volume Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Product Type
12.2.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.2.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.4. Market Revenue and Volume Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Product Type
12.2.5.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.5.4. Market Revenue and Volume Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Product Type
12.2.6.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.6.4. Market Revenue and Volume Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Product Type
12.2.7.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.7.4. Market Revenue and Volume Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Product Type
12.2.8.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.8.4. Market Revenue and Volume Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Product Type
12.3.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.3.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.4. Market Revenue and Volume Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Product Type
12.3.5.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.5.4. Market Revenue and Volume Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Product Type
12.3.6.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.6.4. Market Revenue and Volume Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Product Type
12.3.7.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.7.4. Market Revenue and Volume Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Product Type
12.3.8.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.8.4. Market Revenue and Volume Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Product Type
12.4.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.4.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.4. Market Revenue and Volume Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Product Type
12.4.5.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.5.4. Market Revenue and Volume Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Product Type
12.4.6.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.6.4. Market Revenue and Volume Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Product Type
12.4.7.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.7.4. Market Revenue and Volume Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Product Type
12.4.8.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.8.4. Market Revenue and Volume Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Product Type
12.5.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.4. Market Revenue and Volume Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Product Type
12.5.5.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.5.4. Market Revenue and Volume Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Product Type
12.5.6.2. Market Revenue and Volume Forecast, by Stage of Alzheimer’s Disease
12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.6.4. Market Revenue and Volume Forecast, by End User
13.1. AbbVie
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial PerProduct Typeance
13.1.4. Recent Initiatives
13.2. Johnson & Johnson
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial PerProduct Typeance
13.2.4. Recent Initiatives
13.3. Takeda Pharmaceutical
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial PerProduct Typeance
13.3.4. Recent Initiatives
13.4. GlaxoSmithkline (GSK)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial PerProduct Typeance
13.4.4. Recent Initiatives
13.5. Pfizer, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial PerProduct Typeance
13.5.4. Recent Initiatives
13.6. Merck & Co.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial PerProduct Typeance
13.6.4. Recent Initiatives
13.7. H. Lundbeck A/S
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial PerProduct Typeance
13.7.4. Recent Initiatives
13.8. Daiichi Sankyo Co., Ltd.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial PerProduct Typeance
13.8.4. Recent Initiatives
13.9. Abbott
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial PerProduct Typeance
13.9.4. Recent Initiatives
13.10. AC Immune
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial PerProduct Typeance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
